Contrasting effects of extended low dose versus standard dose shorter course UFT chemotherapy on microscopic versus macroscopic established tumors: Implications for optimal postoperative adjuvant chemotherapy

Junji Uchida, Hiroyuki Okabe, Koushi Nakano, Akio Fujioka, Hitoshi Saito, Yoshikazu Sugimoto, Toshinori Oka, Masakazu Fukushima

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Given such differences as relative tumor burden, the optimal dose and schedule for postoperative adjuvant chemotherapy of microscopic disease might be expected to differ significantly from therapy of advanced higher volume disease. We investigated this hypothesis by determining the optimal dose and schedule of the 5-FU pro-drug, UFT, for treatment of early versus later stage disease models of the Lewis lung carcinoma (LLC). Postoperative adjuvant therapy of early stage disease was modeled by intravenous injection of LLC cells and initiating therapy one day later, thus simulating the presence of micrometastases at the time of surgery. As a model of 'late' stage disease, a LLC fragment was implanted subcutaneously and UFT therapy was initiated when the tumor was firmly established and had grown to >5 mm in size. A number of UFT dosing protocols were evaluated such as short-term (daily, for 7 days) maximum tolerated dosing (MTD), e.g. 31 mg/kg/day, or a much longer-term (e.g., daily, for up to 60 days) repetitive dosing using doses such as 24 mg/kg/day (the MTD) or lower. The long-term consecutive administration of UFT at relatively low minimally toxic dose levels is a superior dosing regimen in the postoperative adjuvant chemotherapy model; in contrast, the short-term higher dose protocols were superior for treatment of more advanced, established cancer. In addition, the efficacy of UFT in an adjuvant setting is more effective when drug administration is continued for longer periods and when treatment is initiated at progressively earlier time points, after disease establishment.

Original languageEnglish
Pages (from-to)313-319
Number of pages7
JournalOncology Reports
Volume18
Issue number2
Publication statusPublished - 2007 Aug
Externally publishedYes

Fingerprint

Adjuvant Chemotherapy
Lewis Lung Carcinoma
Drug Therapy
Neoplasms
Appointments and Schedules
Therapeutics
Neoplasm Micrometastasis
Poisons
Prodrugs
Cell- and Tissue-Based Therapy
Tumor Burden
Intravenous Injections
Fluorouracil
Pharmaceutical Preparations

Keywords

  • Postoperative adjuvant chemotherapy
  • Treatment schedule
  • Uracil and tegafur

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Contrasting effects of extended low dose versus standard dose shorter course UFT chemotherapy on microscopic versus macroscopic established tumors : Implications for optimal postoperative adjuvant chemotherapy. / Uchida, Junji; Okabe, Hiroyuki; Nakano, Koushi; Fujioka, Akio; Saito, Hitoshi; Sugimoto, Yoshikazu; Oka, Toshinori; Fukushima, Masakazu.

In: Oncology Reports, Vol. 18, No. 2, 08.2007, p. 313-319.

Research output: Contribution to journalArticle

Uchida, Junji ; Okabe, Hiroyuki ; Nakano, Koushi ; Fujioka, Akio ; Saito, Hitoshi ; Sugimoto, Yoshikazu ; Oka, Toshinori ; Fukushima, Masakazu. / Contrasting effects of extended low dose versus standard dose shorter course UFT chemotherapy on microscopic versus macroscopic established tumors : Implications for optimal postoperative adjuvant chemotherapy. In: Oncology Reports. 2007 ; Vol. 18, No. 2. pp. 313-319.
@article{4600e863c4a7475f872bac31c89d6d13,
title = "Contrasting effects of extended low dose versus standard dose shorter course UFT chemotherapy on microscopic versus macroscopic established tumors: Implications for optimal postoperative adjuvant chemotherapy",
abstract = "Given such differences as relative tumor burden, the optimal dose and schedule for postoperative adjuvant chemotherapy of microscopic disease might be expected to differ significantly from therapy of advanced higher volume disease. We investigated this hypothesis by determining the optimal dose and schedule of the 5-FU pro-drug, UFT, for treatment of early versus later stage disease models of the Lewis lung carcinoma (LLC). Postoperative adjuvant therapy of early stage disease was modeled by intravenous injection of LLC cells and initiating therapy one day later, thus simulating the presence of micrometastases at the time of surgery. As a model of 'late' stage disease, a LLC fragment was implanted subcutaneously and UFT therapy was initiated when the tumor was firmly established and had grown to >5 mm in size. A number of UFT dosing protocols were evaluated such as short-term (daily, for 7 days) maximum tolerated dosing (MTD), e.g. 31 mg/kg/day, or a much longer-term (e.g., daily, for up to 60 days) repetitive dosing using doses such as 24 mg/kg/day (the MTD) or lower. The long-term consecutive administration of UFT at relatively low minimally toxic dose levels is a superior dosing regimen in the postoperative adjuvant chemotherapy model; in contrast, the short-term higher dose protocols were superior for treatment of more advanced, established cancer. In addition, the efficacy of UFT in an adjuvant setting is more effective when drug administration is continued for longer periods and when treatment is initiated at progressively earlier time points, after disease establishment.",
keywords = "Postoperative adjuvant chemotherapy, Treatment schedule, Uracil and tegafur",
author = "Junji Uchida and Hiroyuki Okabe and Koushi Nakano and Akio Fujioka and Hitoshi Saito and Yoshikazu Sugimoto and Toshinori Oka and Masakazu Fukushima",
year = "2007",
month = "8",
language = "English",
volume = "18",
pages = "313--319",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - Contrasting effects of extended low dose versus standard dose shorter course UFT chemotherapy on microscopic versus macroscopic established tumors

T2 - Implications for optimal postoperative adjuvant chemotherapy

AU - Uchida, Junji

AU - Okabe, Hiroyuki

AU - Nakano, Koushi

AU - Fujioka, Akio

AU - Saito, Hitoshi

AU - Sugimoto, Yoshikazu

AU - Oka, Toshinori

AU - Fukushima, Masakazu

PY - 2007/8

Y1 - 2007/8

N2 - Given such differences as relative tumor burden, the optimal dose and schedule for postoperative adjuvant chemotherapy of microscopic disease might be expected to differ significantly from therapy of advanced higher volume disease. We investigated this hypothesis by determining the optimal dose and schedule of the 5-FU pro-drug, UFT, for treatment of early versus later stage disease models of the Lewis lung carcinoma (LLC). Postoperative adjuvant therapy of early stage disease was modeled by intravenous injection of LLC cells and initiating therapy one day later, thus simulating the presence of micrometastases at the time of surgery. As a model of 'late' stage disease, a LLC fragment was implanted subcutaneously and UFT therapy was initiated when the tumor was firmly established and had grown to >5 mm in size. A number of UFT dosing protocols were evaluated such as short-term (daily, for 7 days) maximum tolerated dosing (MTD), e.g. 31 mg/kg/day, or a much longer-term (e.g., daily, for up to 60 days) repetitive dosing using doses such as 24 mg/kg/day (the MTD) or lower. The long-term consecutive administration of UFT at relatively low minimally toxic dose levels is a superior dosing regimen in the postoperative adjuvant chemotherapy model; in contrast, the short-term higher dose protocols were superior for treatment of more advanced, established cancer. In addition, the efficacy of UFT in an adjuvant setting is more effective when drug administration is continued for longer periods and when treatment is initiated at progressively earlier time points, after disease establishment.

AB - Given such differences as relative tumor burden, the optimal dose and schedule for postoperative adjuvant chemotherapy of microscopic disease might be expected to differ significantly from therapy of advanced higher volume disease. We investigated this hypothesis by determining the optimal dose and schedule of the 5-FU pro-drug, UFT, for treatment of early versus later stage disease models of the Lewis lung carcinoma (LLC). Postoperative adjuvant therapy of early stage disease was modeled by intravenous injection of LLC cells and initiating therapy one day later, thus simulating the presence of micrometastases at the time of surgery. As a model of 'late' stage disease, a LLC fragment was implanted subcutaneously and UFT therapy was initiated when the tumor was firmly established and had grown to >5 mm in size. A number of UFT dosing protocols were evaluated such as short-term (daily, for 7 days) maximum tolerated dosing (MTD), e.g. 31 mg/kg/day, or a much longer-term (e.g., daily, for up to 60 days) repetitive dosing using doses such as 24 mg/kg/day (the MTD) or lower. The long-term consecutive administration of UFT at relatively low minimally toxic dose levels is a superior dosing regimen in the postoperative adjuvant chemotherapy model; in contrast, the short-term higher dose protocols were superior for treatment of more advanced, established cancer. In addition, the efficacy of UFT in an adjuvant setting is more effective when drug administration is continued for longer periods and when treatment is initiated at progressively earlier time points, after disease establishment.

KW - Postoperative adjuvant chemotherapy

KW - Treatment schedule

KW - Uracil and tegafur

UR - http://www.scopus.com/inward/record.url?scp=34548529602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548529602&partnerID=8YFLogxK

M3 - Article

C2 - 17611650

AN - SCOPUS:34548529602

VL - 18

SP - 313

EP - 319

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 2

ER -